Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Expert Rev Anticancer Ther. 2011 Mar;11(3):373-86. doi: 10.1586/era.10.193.
Targeted therapy is a very exciting era in the treatment of squamous cell carcinomas of the head and neck. After adding cetuximab to conventional chemotherapy and radiation therapy, we are strongly considering the role of induction chemotherapy with the addition of docetaxel. At the same time, other new treatments, especially targeted agents and novel combined regimens, are being evaluated in ongoing clinical trials. For example, several trials are attempting to combine docetaxel and cetuximab in chemoradiation or induction settings. However, in the near future we are likely to see a strong presence of targeted agents that have been found to be not only effective, but also less toxic than conventional chemotherapeutic agents. Their toxicity profiles make them eligible for addition to radiation treatment strategies, as well as other chemotherapy agents, or even for replacing these chemotherapy agents. In this article, we are going to review the indications and current role of cetuximab, tyrosine kinase inhibitors (gefitinib and erlotinib), dual inhibitors, IGF receptor inhibitors, as well as other agents that are in development for treatment of head and neck squamous cell carcinomas.
靶向治疗是头颈部鳞状细胞癌治疗中一个非常令人兴奋的时代。在常规化疗和放疗中加入西妥昔单抗后，我们强烈考虑在诱导化疗中加入多西他赛。同时，其他新的治疗方法，特别是靶向药物和新的联合方案，正在进行中的临床试验中进行评估。例如，几项试验试图在放化疗或诱导治疗中联合多西他赛和西妥昔单抗。然而，在不久的将来，我们很可能会看到靶向药物的大量应用，这些药物不仅有效，而且比传统的化疗药物毒性更小。它们的毒性特征使它们有资格添加到放射治疗策略中，以及其他化疗药物，甚至可以替代这些化疗药物。在本文中，我们将回顾西妥昔单抗、酪氨酸激酶抑制剂（吉非替尼和厄洛替尼）、双重抑制剂、IGF 受体抑制剂以及其他用于治疗头颈部鳞状细胞癌的开发中的药物的适应证和当前作用。
